Skip to the main content.

Cell and Gene Therapy Series. Part 4 - Managing costs and scale-up risks for medical devices

Dr. Dave Seaward : 28 February 2022

Cell and Gene Therapy Series. Part 4 - Managing costs and scale-up risks for medical devices

As we continue to explore the world of cell and gene therapy, we now take a look at managing costs and scale up risks for medical devices.

Author Dave Seward, discusses how the principles of Quality by Design (QbD) and Design for Manufacture (DfM) can be applicable to ATMPs. Read this blog now!
Pouching solutions for sterile and moisture-sensitive devices

Pouching solutions for sterile and moisture-sensitive devices

David Phasey: 20 May 2026

Pouches are widely used in medical device packaging to provide a sterile barrier when the device itself, or its primary container, cannot inherently...

Read More
Interview with Founder Tom Bailey: Blister Dose Delivery Uniformity (DDU)

Interview with Founder Tom Bailey: Blister Dose Delivery Uniformity (DDU)

Georgia Lewis: 18 May 2026

Dose Delivery Uniformity (DDU) is one of the most persistent challenges in dry-powder inhaler development, and few have tackled it more directly...

Read More
How our robotic isolator technology is setting a new standard for aseptic fill-finish

How our robotic isolator technology is setting a new standard for aseptic fill-finish

David Johnson: 15 April 2026

In the world of pharmaceutical manufacturing, our robotic isolator technology sets a new standard for aseptic fill-finish technology. By integrating...

Read More